Substance / Medication

Isoprenaline hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

12
Total Trials
1
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Malaty Michael, Kayes Tahrima, Amarasekera Anjalee T et al. · Eur J Clin Invest · 2021
PMID: 33043453Meta-AnalysisFull text (PMC)
Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes.
Krisai Philipp, Vlachos Konstantinos, Ramirez F Daniel et al. · J Cardiovasc Electrophysiol · 2020
PMID: 32700358Meta-Analysis
Validation and Clinical Utility of the hERG IC50:CRatio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis.
Lehmann David F, Eggleston William D, Wang Dongliang · Pharmacotherapy · 2018
PMID: 29380488Meta-Analysis
Ameliorative effect of ferruginol on isoprenaline hydrochloride-induced myocardial infarction in rats.
Zhang Xudong, Li Xiaojiang, Wang Chunlan et al. · Environ Toxicol · 2021
PMID: 32946155Preclinical
Alleviation of isoprenaline hydrochloride induced myocardial ischemia injury by brucine through the inhibition of Na+/K+-ATPase.
Liu Bin, Zhang Yuqing, Wu Qingke et al. · Exp Gerontol · 2021
PMID: 33781843Preclinical
An insight into the inhibition of fibrillation process verses disaggregation of preformed fibrils of bovine serum albumin by isoprenaline hydrochloride.
Chandel Tajalli Ilm, Afghani Mariyam, Masroor Aiman et al. · Int J Biol Macromol · 2020
PMID: 31778695Preclinical
Phloroglucinol averts isoprenaline hydrochloride induced myocardial infarction in rats.
Zhu Canzhan, Li Wanjing, Wang Xinhong et al. · Drug Dev Res · 2019
PMID: 30889286Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Isoprenaline hydrochloride (substance)
SNOMED CT
29301006
UMLS CUI
C0282210

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.